Alvotech application for Simponi biosimilar accepted by EMA

Biosimilars pharmaceutical drug bottle on blue background. A safe biological drug that work like biologic medicine. 3d illustration.

Carl Lokko/iStock via Getty Images

  • The European Medicines Agency has accepted a Marketing Authorization Application for AVT05, Alvotech’s (NASDAQ:ALVO) biosimilar to Johnson & Johnson’s (JNJ) TNF blocker Simponi (golimumab).
  • Alvotech is expecting approval in Q4 2025.
  • In April, the Icelandic drugmaker released top-line results of a

Leave a Reply

Your email address will not be published. Required fields are marked *